Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies^[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets^[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ: ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ: AVBP), Merus N.V. (NASDAQ: MRUS), and Halozyme Therapeutics, Inc. (NASDAQ: HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal cancers.